Related Experiment Video
Updated: Jan 22, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p32 is a negative regulator of p53 tetramerization and transactivation
Nikhil Baban Ghate1, Jinman Kim1, Yonghwan Shin1
1Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Abstract:
p53 is a sequence-specific transcription factor, and proper regulation of p53 transcriptional activity is critical for orchestrating different tumor-suppressive mechanisms. p32 is a multifunctional protein which interacts with a large number of viral proteins and transcription factors. Here, we investigate the effect of p32 on p53 transactivation and identify a novel mechanism by which p32 alters the functional characteristics of p53. Specifically, p32 attenuates p53-dependent transcription through impairment of p53 binding to its response elements on target genes. Upon p32 expression, p53 levels bound at target genes are decreased, and p53 target genes are inactivated, strongly indicating that p32 restricts p53 occupancy and function at target genes. The primary mechanism contributing to the observed action of p32 is the ability of p32 to interact with the p53 tetramerization domain and to block p53 tetramerization, which in turn enhances nuclear export and degradation of p53, leading to defective p53 transactivation. Collectively, these data establish p32 as a negative regulator of p53 function and suggest the therapeutic potential of targeting p32 for cancer treatment.
Insights
The protein p32 negatively regulates the tumor suppressor p53 by blocking its DNA binding and promoting its degradation. This finding reveals p32 as a potential therapeutic target for cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Biology
- Biochemistry
Background:
- p53 is a crucial tumor suppressor that regulates cell cycle arrest and apoptosis.
- Dysregulation of p53 activity is common in cancer.
- p32 is a multifunctional protein known to interact with various viral and cellular proteins.
Purpose of the Study:
- To investigate the effect of p32 on p53 transcriptional activity.
- To elucidate the mechanism by which p32 influences p53 function.
- To assess the potential of targeting p32 in cancer therapy.
Main Methods:
- Assessing p53 transactivation in the presence of p32.
- Analyzing p53 binding to target gene response elements.
- Investigating the interaction between p32 and the p53 tetramerization domain.
- Evaluating the impact of p32 on p53 nuclear export and degradation.
Main Results:
- p32 attenuates p53-dependent transcription.
- p32 impairs p53 binding to its response elements.
- p32 interacts with the p53 tetramerization domain, blocking tetramerization.
- p32 enhances p53 nuclear export and degradation, leading to reduced p53 transactivation.
Conclusions:
- p32 acts as a negative regulator of p53 tumor-suppressive functions.
- p32 inhibits p53 by disrupting its DNA binding and promoting its degradation.
- Targeting p32 may offer a novel therapeutic strategy for cancer treatment.
Related Concept Videos
Negative Regulator Molecules
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Epigenetic Regulation
GTPases and their Regulation
Large G-proteins,...
Positive, Negative, and Zero Work
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

